Project Grant R03CA304044
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$168K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $147,486 to Yale University to characterize and define the role of glycosylated RNAs (glycoRNAs) in acute myeloid leukemia (AML). The project aims to: 1) characterize glycoRNA expression and sequences in different AML subtypes and normal myeloid progenitors, 2) define the role of SIDT proteins in AML glycoRNA expression, and 3) determine the functions of glycoRNAs in AML biology, including...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,419,108 to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The award will fund research to gain insights into how blocking the SEMA4D signaling pathway, when combined with immune checkpoint blockade, enhances the activity of antigen-presenting dendritic...
This federal Project Grant award of $499,238 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Yale University focused on enhancing the effects of DNA-damaging cancer therapies through modulation of the STING (Stimulator of Interferon Genes) pathway. The key goals are to develop a novel tumor-targeted STING agonist formulation, test its synergistic effects with DNA-damaging treatments in a STING-dependent manner, and identify the immunological...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
The National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health, awarded a $101,340 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Michigan. The award will fund research to investigate the role of the MS4A14 protein in regulating macrophage activation and antigen presentation, with the goal of improving immunotherapy response in cancer patients. The research...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...
This federal Project Grant award of $138,846 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop "lab-generated 'wild-like' mice" that mimic the adult human immune system. The goal is to create mouse models that better recapitulate human responses to cancer and immunotherapy, enabling more effective translation of findings from mouse studies to human treatments. The award was granted to the University Health...